Jiuxiang Zhu

1.2k total citations
11 papers, 1.0k citations indexed

About

Jiuxiang Zhu is a scholar working on Molecular Biology, Pharmacology and Genetics. According to data from OpenAlex, Jiuxiang Zhu has authored 11 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Pharmacology and 4 papers in Genetics. Recurrent topics in Jiuxiang Zhu's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Inflammatory mediators and NSAID effects (4 papers). Jiuxiang Zhu is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Inflammatory mediators and NSAID effects (4 papers). Jiuxiang Zhu collaborates with scholars based in United States, Australia and Canada. Jiuxiang Zhu's co-authors include Ching-Shih Chen, Kenneth W. Kinzler, Bert Vogelstein, Oleg Schmidt‐Kittler, Ching‐Shih Chen, Ping‐Hui Tseng, Sandra B. Gabelli, Chuan‐Hsiang Huang, Zhimin Tong and Xuli Wu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Cancer Research.

In The Last Decade

Jiuxiang Zhu

11 papers receiving 988 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiuxiang Zhu United States 11 576 189 163 162 161 11 1.0k
Brian Bolognese United States 18 522 0.9× 94 0.5× 44 0.3× 75 0.5× 265 1.6× 34 1.2k
Peter Norman United Kingdom 18 436 0.8× 188 1.0× 145 0.9× 138 0.9× 202 1.3× 100 1.3k
Gerald Nabozny United States 23 309 0.5× 85 0.4× 50 0.3× 172 1.1× 198 1.2× 54 1.5k
Chi‐Kuang Huang United States 22 925 1.6× 97 0.5× 34 0.2× 64 0.4× 244 1.5× 36 1.7k
Alain De Pover Switzerland 16 1.2k 2.1× 67 0.4× 174 1.1× 139 0.9× 341 2.1× 25 1.6k
Maria Chiara De Santis Italy 14 1.0k 1.8× 49 0.3× 107 0.7× 56 0.3× 287 1.8× 18 1.6k
Galina Kuznetsov United States 19 873 1.5× 126 0.7× 33 0.2× 117 0.7× 578 3.6× 30 1.8k
Yanling Wu China 19 934 1.6× 34 0.2× 33 0.2× 110 0.7× 252 1.6× 41 1.4k
Yasunori Yokota Japan 16 573 1.0× 55 0.3× 44 0.3× 26 0.2× 79 0.5× 19 956
G.J. Brunn United States 8 800 1.4× 47 0.2× 48 0.3× 57 0.4× 162 1.0× 8 1.1k

Countries citing papers authored by Jiuxiang Zhu

Since Specialization
Citations

This map shows the geographic impact of Jiuxiang Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiuxiang Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiuxiang Zhu more than expected).

Fields of papers citing papers by Jiuxiang Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiuxiang Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiuxiang Zhu. The network helps show where Jiuxiang Zhu may publish in the future.

Co-authorship network of co-authors of Jiuxiang Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Jiuxiang Zhu. A scholar is included among the top collaborators of Jiuxiang Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiuxiang Zhu. Jiuxiang Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Zheng, Zhaohua, Jiuxiang Zhu, Oleg Schmidt‐Kittler, et al.. (2012). Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis. Biochemical Journal. 444(3). 529–535. 24 indexed citations
2.
Schmidt‐Kittler, Oleg, Jiuxiang Zhu, Ian G. Jennings, et al.. (2011). Thiazolidinedione‐Based PI3Kα Inhibitors: An Analysis of Biochemical and Virtual Screening Methods. ChemMedChem. 6(3). 514–522. 15 indexed citations
3.
Schmidt‐Kittler, Oleg, Jiuxiang Zhu, Jian Yang, et al.. (2010). PI3Kα Inhibitors That Inhibit Metastasis. Oncotarget. 1(5). 339–348. 36 indexed citations
4.
Mandelker, Diana, Sandra B. Gabelli, Oleg Schmidt‐Kittler, et al.. (2009). A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane. Proceedings of the National Academy of Sciences. 106(40). 16996–17001. 234 indexed citations
5.
Suphioglu, Cenk, Jiuxiang Zhu, Oleg Schmidt-Kittler, et al.. (2008). Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. Biochemical Journal. 414(3). 383–390. 43 indexed citations
6.
Tseng, Ping‐Hui, Jiuxiang Zhu, Kuen‐Feng Chen, et al.. (2005). Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood. 105(10). 4021–4027. 52 indexed citations
7.
Kucab, Jill E., Cathy Lee, Ching‐Shih Chen, et al.. (2005). Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Research. 7(5). R796–807. 76 indexed citations
8.
Tong, Zhimin, Xuli Wu, Dmitriy Ovcharenko, et al.. (2005). Neutrophil gelatinase-associated lipocalin as a survival factor. Biochemical Journal. 391(2). 441–448. 155 indexed citations
9.
Zhu, Jiuxiang, Jui-Wen Huang, Ping‐Hui Tseng, et al.. (2004). From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors. Cancer Research. 64(12). 4309–4318. 215 indexed citations
10.
11.
Ding, Haiming, Chunhua Han, Jiuxiang Zhu, Ching‐Shih Chen, & Steven M. D’Ambrosio. (2004). Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. International Journal of Cancer. 113(5). 803–810. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian Bolognese Breakdown of academic impact, for papers by Peter Norman Breakdown of academic impact, for papers by Gerald Nabozny Breakdown of academic impact, for papers by Chi‐Kuang Huang Breakdown of academic impact, for papers by Alain De Pover Breakdown of academic impact, for papers by Maria Chiara De Santis Breakdown of academic impact, for papers by Galina Kuznetsov Breakdown of academic impact, for papers by Yanling Wu Breakdown of academic impact, for papers by Yasunori Yokota Breakdown of academic impact, for papers by G.J. Brunn
Rankless by CCL
2026